Purple Yam (Dioscorea alata) Extract Increasing Dopamine Levels and Improving the Brain's Microscopic Features in Parkinson's Model Mice
Open Access
- 30 May 2025
- journal article
- Published by Universitas Muhammadiyah Palangkaraya in Borneo Journal of Pharmacy
- Vol. 8 (2) , 127-134
Abstract
Parkinson's disease (PD) is a severe neurodegenerative disorder, that causes progressive motor issues from the loss of dopamine-producing neurons in the substantia nigra pars compacta (SNpc). Purple yam (Dioscorea alata), rich in anthocyanins, shows promise as a natural antioxidant and neuroprotectant. This study investigated the antiparkinsonian effects of D. alata extract on dopamine levels and brain microscopic features in a haloperidol-induced PD mouse model. Thirty-five male mice were randomly allocated into seven groups: normal (CMC-Na and aqua pro injection), haloperidol-induced negative control (CMC-Na), positive control (levodopa 39 mg/kgBW), curcumin (200 mg/kgBW), and D. alata extract-treated groups (100, 200, and 400 mg/kgBW). Treatments were administered daily for seven days. On day 8, all groups, except the normal control, received an intraperitoneal injection of haloperidol (2 mg/kgBW) to induce Parkinsonism. Three hours post-haloperidol injection, dopamine levels were measured from orbital vein blood. Subsequently, brains were harvested for histological examination of the SNpc using Toluidine blue staining. Data were statistically analyzed using one-way ANOVA followed by LSD post-hoc tests. The 400 mg/kgBW dose of D. alata extracts significantly increased dopamine levels (p<0.05) compared to the negative control group. Microscopic analysis of the SNpc in mice treated with 400 mg/kgBW extract revealed preserved, dark, and solid neuronal morphology, with significantly higher scoring results (p<0.05) when compared to the levodopa-treated group. These findings suggest that D. alata extract, particularly at a dose of 400 mg/kgBW, exhibits potential antiparkinsonian activity by elevating dopamine levels and mitigating dopaminergic neuronal damage in a haloperidol-induced PD mouse model.Keywords
This publication has 29 references indexed in Scilit:
- Recent updates on structural insights of MAO-B inhibitors: a review on target-based approachMolecular Diversity, 2023
- Development of Prodrugs for Treatment of Parkinson‘s Disease: New Inorganic Scaffolds for Blood–Brain Barrier PermeationJournal of Pharmaceutical Sciences, 2022
- Levodopa-induced dyskinesia: a historical review of Parkinson’s disease, dopamine, and modern advancements in research and treatmentJournal of Neurology, 2022
- Neuroprotective effects of Ginkgo biloba dropping pills in Parkinson’s diseaseJournal of Pharmaceutical Analysis, 2021
- Mucuna pruriens in Parkinson’s and in some other diseases: recent advancement and future prospective3 Biotech, 2020
- Neuroprotective potential of Myrica esulenta in Haloperidol induced Parkinson’s diseaseJournal of Ayurveda and Integrative Medicine, 2020
- Anti-Parkinson’s Activity of Tribulus terrestris via Modulation of AChE, α-Synuclein, TNF-α, and IL-1βACS Omega, 2020
- Exploring the Therapeutic Potentials of Highly Selective Oxygenated Chalcone Based MAO-B Inhibitors in a Haloperidol-Induced Murine Model of Parkinson’s DiseaseNeurochemical Research, 2020
- Parkinson Disease Epidemiology, Pathology, Genetics, and PathophysiologyClinics in Geriatric Medicine, 2020
- Neuroprotective effects of anthocyanin- and proanthocyanidin-rich extracts in cellular models of Parkinson׳s diseaseBrain Research, 2014